GARDEN CITY, N.Y., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Beyond Cancer, Ltd., a clinical stage biotechnology company developing ultra-high concentration nitric oxide (UNO) as an immunotherapeutic for solid tumors and subsidiary of Beyond Air, Inc. (NASDAQ: XAIR), today announced being selected to present an abstract featuring data from the Phase 1 trial of intratumoral UNO in solid tumor metastases at the American Association for Cancer Research (AACR) Annual Meeting 2026, which is scheduled to be held from Fri ...

GARDEN CITY, N.Y., Jan. 26, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced that it will report financial results for its third fiscal quarter ended December 31, 2025 on Friday, February 13, 2026. The Company's management team is scheduled to host a conference call and webcast at 8:00 am Eastern Time t ...

Summary of Beyond Air (NasdaqCM:XAIR) FY Conference Call Company Overview - **Company**: Beyond Air - **Ticker**: XAIR - **Industry**: Medical Gas (Nitric Oxide) Key Points Product and Technology - **Nitric Oxide (NO)**: A medical gas used primarily as a pulmonary vasodilator to treat conditions like hypoxic respiratory failure in newborns and right ventricular dysfunction post-cardiac surgery [4][5] - **Unique Selling Proposition**: Beyond Air's system generates nitric oxide from room air, eliminating the need for heavy, hazardous cylinders used by competitors, making it more sustainable and cost-effective for hospitals [6][8][10] Market Challenges and Strategy - **Slow Uptake in U.S. Market**: Initial launch difficulties due to the pandemic and compatibility issues with upgraded ventilators delayed market penetration [11][12] - **First-Generation System Limitations**: The first-generation device lacks inter-hospital transport capabilities, which is a drawback in the U.S. market [13] - **Second-Generation Device**: Anticipated FDA approval by the end of 2026, designed to be smaller, user-friendly, and suitable for transport in ambulances and aircraft [14][16] Market Potential - **International Market**: Beyond Air has established distribution partnerships in 40 countries, with expectations of significant revenue growth from international markets over the next 12 to 24 months [18][25] - **Market Size Comparison**: The international market for nitric oxide is projected to be double that of the U.S. market in terms of dollar value over the next five to seven years [21] Clinical Pipeline - **Infectious Diseases**: Ongoing studies on the use of nitric oxide for treating lung infections and COVID-19, with positive results from previous trials [27][29] - **Cancer Treatment**: Research on high-dose nitric oxide for cancer treatment shows promising survival signals in refractory patients [31][34] - **Neurological Conditions**: Preclinical studies on conditions like autism and glioblastoma, with orphan drug status granted by the FDA [35][36] Intellectual Property - **Patent Portfolio**: Strong patent protection for the LungFit machine and related technologies, with patents extending to 2044 [37][39] Financial Position - **Capital Position**: Recent funding has strengthened the balance sheet, providing enough cash to reach the next-generation product approval, with potential needs for additional capital for a proper launch [40][41] Conclusion - Beyond Air is positioned to capture significant market share in the nitric oxide space with its innovative technology and expanding international presence, despite initial challenges in the U.S. market. The company is actively pursuing clinical applications in infectious diseases, cancer, and neurological conditions, supported by a robust patent portfolio and a solid financial foundation.

Core Viewpoint - Beyond Air, Inc. has entered into a securities purchase agreement to raise approximately $5.0 million through a private placement of common stock and warrants, aimed at enhancing its working capital and general corporate purposes [1][2]. Group 1: Securities Offering - The company will issue 3,930,818 shares of common stock and warrants to purchase an equal number of shares at a combined purchase price of $1.272 per share, with expected gross proceeds of around $5.0 million before expenses [1]. - The warrants will have an exercise price of $1.147 per share and will be exercisable immediately upon issuance for a term of five years [1]. - Rodman & Renshaw LLC is the exclusive placement agent for this private placement, with Roth Capital Partners and D. Boral Capital serving as financial advisors [2]. Group 2: Use of Proceeds - The net proceeds from the private placement will be utilized for working capital and general corporate purposes [2]. Group 3: Company Overview - Beyond Air is a commercial-stage medical device and biopharmaceutical company focused on using nitric oxide to treat respiratory illnesses, neurological disorders, and solid tumors [5]. - The company has received FDA approval and CE Mark for its LungFit PH system, which treats neonates with hypoxic respiratory failure, and is advancing other LungFit systems in clinical trials for severe lung infections [5]. - An affiliate, Beyond Cancer, Ltd., is exploring ultra-high concentrations of nitric oxide for targeting solid tumors in pre-clinical settings [6].

Market Performance - U.S. stocks showed mixed performance with the Dow Jones index falling over 200 points, down 0.60% to 49,293.33, while the NASDAQ gained 0.17% to 23,773.29 and the S&P 500 dropped 0.08% to 6,971.95 [1] - In the energy sector, shares increased by 1.4%, while financial stocks decreased by 1.8% [1] Inflation Data - Inflation remained steady in December, with the Consumer Price Index rising 2.7% year over year, matching economist expectations and unchanged from November [2] - Monthly consumer prices increased by 0.3%, also in line with forecasts [2] Commodity Prices - Oil prices rose by 2.6% to $61.06, while gold increased by 0.1% to $4,620.80 [4] - Silver prices surged by 4.4% to $88.860, whereas copper fell by 0.1% to $6.0295 [4] European Market Trends - European shares were mixed, with the eurozone's STOXX 600 falling 0.08% and Spain's IBEX 35 Index rising 0.08% [5] - London's FTSE 100 slipped 0.03%, Germany's DAX gained 0.06%, and France's CAC 40 fell 0.14% [5] Asian Market Performance - Asian markets closed mixed, with Japan's Nikkei surging 3.10% and Hong Kong's Hang Seng Index gaining 0.90% [8] - Conversely, China's Shanghai Composite fell 0.64% and India's BSE Sensex decreased by 0.30% [8] Company-Specific Movements - Beyond Air Inc shares surged 172% to $2.39 following an acquisition agreement, potentially receiving up to $32.5 million [7] - Ambitions Enterprise Management Co LLC shares increased by 106% to $10.90 due to a year-over-year EPS increase [7] - TryHard Holdings Ltd shares rose by 77% to $40.96 after announcing a collaboration agreement and a $10 million share repurchase program [7] - Signing Day Sports Inc shares dropped 57% to $0.25 after announcing a public offering [7] - Travere Therapeutics Inc shares fell 32% to $23.16 following preliminary fourth-quarter financial results [7] - Wealthfront Corp shares decreased by 18% to $10.34 due to weak quarterly sales [7]

U.S. stocks traded lower this morning, with the Dow Jones index falling more than 300 points on Tuesday.Following the market opening Tuesday, the Dow traded down 0.66% to 49,264.22 while the NASDAQ declined 0.15% to 23,699.14. The S&P 500 also fell, dropping, 0.24% to 6,960.41.Check This Out: Bank of America Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street’s Most Accurate AnalystsLeading and Lagging SectorsEnergy shares gained by 1.4% on Tuesday.In trading on Tuesday, financial s ...

Core Insights - XTL Biopharmaceuticals Ltd. has announced a binding agreement to acquire 85% of NeuroNOS Ltd., a subsidiary of Beyond Air, Inc., which focuses on disease-modifying therapeutics for Autism Spectrum Disorder (ASD) and neuro-oncology [1][2] - The acquisition positions XTL as a significant player in the autism therapeutics market, addressing a critical unmet medical need as 1 in 31 U.S. children are affected by autism, with no FDA-approved disease-modifying therapies currently available [3][4] Company Overview - NeuroNOS was founded by Professor Haitham Amal, a leading autism researcher, and has strengthened its scientific leadership by adding two Nobel Laureates in Chemistry, enhancing its potential for therapeutic innovation [5][7] - The company’s drug development platform targets the underlying molecular mechanisms of autism through a proprietary family of small molecules that can cross the blood-brain barrier [8] Market Opportunity - The autism crisis has led to increased strain on healthcare systems and families, with a significant rise in cases prompting urgent calls for new therapeutic pathways and research funding from U.S. policymakers [3][4] - The U.S. government has allocated $50 million in new NIH funding for autism research initiatives, indicating a shift in regulatory priorities towards autism treatment development [4] Transaction Details - XTL will acquire 85% of NeuroNOS for a combination of cash, shares, and milestone payments totaling up to $32.5 million, with the transaction subject to shareholder approval [10][11] - The milestone payments include up to $5.5 million for clinical development and up to $26 million for achieving product sales targets [11] Scientific Validation - NeuroNOS has secured FDA Orphan Drug Designations for Phelan-McDermid Syndrome and Glioblastoma, which provide market exclusivity and expedited regulatory review upon approval [9] - Preclinical studies have shown that the platform addresses core pathological mechanisms in autism, validating nitric oxide dysregulation as a therapeutic target [8]

Unmatched scientific firepower: Two Nobel Laureates join Founder Prof. Haitham Amal, leading global autism researcher Critical unmet need: 1 in 31 U.S. children now affected, zero FDA-approved disease-modifying therapies exist FDA Orphan Drug designations secured for autism-related Phelan-McDermid Syndrome (PMS) and Glioblastoma Platform targets the core biology of autism, not just symptomatic relief Beyond Air (NASDAQ: XAIR), majority owner of NeuroNOS, to hold 19.99% of XTL's post-transaction share capita ...

Core Insights - XTL Biopharmaceuticals is acquiring 85% of NeuroNOS, a subsidiary of Beyond Air, to enhance its position in the autism therapeutics market, which is currently underserved with no FDA-approved disease-modifying therapies available [1][2] - The acquisition is expected to provide XTL with a strong scientific foundation, including leadership from Nobel Laureates and a focus on addressing the underlying biological mechanisms of Autism Spectrum Disorder (ASD) [7][12] Industry Overview - Autism Spectrum Disorder affects approximately 1 in 31 children in the U.S., highlighting a significant public health crisis that has strained healthcare systems and families [3][4] - The U.S. government has recognized the urgency of addressing autism, allocating $50 million in new NIH funding for research initiatives, indicating a shift in regulatory priorities towards autism treatment development [4] Scientific Leadership - NeuroNOS was founded by Professor Haitham Amal, a leading autism researcher, and has recently added two Nobel Laureates, enhancing its scientific credibility and potential for innovation in autism therapeutics [5][7] - The company's research focuses on nitric oxide dysregulation, which has been linked to both autism and brain cancer, establishing a novel therapeutic target [6][8] Technology and Regulatory Status - NeuroNOS's drug development platform utilizes small molecules designed to cross the blood-brain barrier and target nitric oxide abnormalities, aiming to address core pathological mechanisms rather than just symptoms [8] - The company has secured FDA Orphan Drug Designations for Phelan-McDermid Syndrome and Glioblastoma, which provide market exclusivity and expedited regulatory review [9] Transaction Details - The acquisition terms include a 19.9% stake in XTL's post-transaction share capital, $1 million in cash, and milestone payments up to $32.5 million based on clinical and commercial achievements [10][11] - Both XTL and Beyond Air are committed to advancing NeuroNOS's autism treatment programs with urgency [11][12]

Group 1: CFO Transition at Robinhood - Jason Warnick is retiring as CFO of Robinhood, with Shiv Verma stepping into the role, focusing on finance and strategy [2][6] - Warnick emphasizes the importance of capital allocation and influencing the CEO in a CFO's role [3] - Verma has engaged with CEO Vlad Tenev and other leaders to focus on long-term strategic decisions for Robinhood [4] Group 2: CEO-CFO Partnership - The partnership between the CEO and CFO is critical, as CFOs are seen as strategic thought partners amid rapid technological changes [5] - CFOs provide enterprise-wide visibility and help translate ambiguity into actionable decisions [5] Group 3: Robinhood's Performance and Governance - Robinhood experienced significant changes over the past seven years, including workforce reductions and a shift to a general manager model [6] - In 2024, Robinhood reported total net revenue of $2.95 billion and annual net income of $1.41 billion, and joined the S&P 500 in September [6][7] Group 4: Tesla's Q4 2025 Performance - Tesla produced over 434,000 vehicles and delivered over 418,000 vehicles in Q4 2025, with energy storage deployments reaching a record of 14.2 GWh [12] - For the full year 2025, Tesla delivered 1.64 million vehicles, a 9% decrease from 2024, while BYD sold 2.26 million electric vehicles, becoming the largest EV maker [13]